Fulminant immune-related colitis after dual checkpoint inhibitor therapy: case report.

Immunotherapy

Department of Medicine, Division of Hematology/Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.

Published: October 2024

Immune-related (IR) colitis is a potentially life-threatening complication of checkpoint inhibitors. Its presentation often includes diarrhea, abdominal pain and rectal bleeding and the median time to onset is 6-10 weeks post initiation of immunotherapy. We report an unusual case of fulminant IR-colitis beginning 3 days after the first dose of dual checkpoint blockade. IR-colitis was refractory to high-dose corticosteroids and was further complicated by sigmoid diverticulum perforation. Early-onset IR-colitis can occur, particularly in the context of combined anti-PD1 and anti-CTLA4 blockade, and clinicians should maintain a high-index of suspicion even when timing of symptom onset is atypical. Further research is needed to elucidate risk factors for early-onset IR-colitis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485820PMC
http://dx.doi.org/10.1080/1750743X.2024.2386234DOI Listing

Publication Analysis

Top Keywords

dual checkpoint
8
early-onset ir-colitis
8
fulminant immune-related colitis
4
immune-related colitis dual
4
checkpoint inhibitor
4
inhibitor therapy
4
therapy case
4
case report
4
report immune-related
4
immune-related colitis
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!